Home ยป Webcast
Tag:

Webcast

Business

Provident Financial Services Announces Earnings Release & Conference Call

by Priya Shah โ€“ Business Editor
written by Priya Shah โ€“ Business Editor

Provident financial Services, Inc. too Host Third Quarter 2025 Earnings Conference โฃCall

Provident Financial Services, Inc., โขthe holding company โ€Œfor Provident Bank, will discuss it’s third quarter 2025 financial results during a conference call on โฃOctober 30, 2025. โขThe call begins at 10:00โ€‹ a.m. (ET) and will beโ€ accessible via โฃlive webcast and telephone.

This earnings call provides investors and stakeholders with criticalโค insight into the performance of Provident Financial services, Inc., a financial institution with $24.5 billion inโฃ assets as of June 30, 2025. The discussion will cover key financial metrics, strategicโข initiatives, and the company’s outlook for the remainder of the year, impacting shareholder value โคand market perception.

Dial-in Data:

* โค US & Canada Toll Free: 1(800) 770-2030
* US Toll: 1(609) 800-9909
* Canada Toll: 1(647) 362-9199
* โ€ International Toll: +1(646) 960-0134
* Conference ID: 3610756

A webcast of the call will be โคavailable at https://www.globenewswire.com/tracker?data=tCmyydKlfuwpVD8JtfNfF23Aqc1YGMgO4n9plOcT6wG9n-KoM6mDT4UF0Ph2_dCtXbusKrmkfESHmBdIqfw3C0FUWTyYRup8Q2Bl9fP0tqU= โข under the “Investor Relations” and “Webcast” sections of www.Provident.Bank.

A replayโฃ of theโ€‹ call โ€‹willโค be โ€‹available from 3:00 p.m.(ET) on October 30, โ€Œ2025,โข until 11:59 p.m. (ET) on November 13, 2025, using โ€‹the Playback ID: 3610756โ€Œ followed by the # key. The โ€Œcall โ€will also be archived onโ€ the Company’s โ€Œwebsite โคfor one year.

Provident Bank operates a network of branches in New Jersey,eastern Pennsylvania,and Orange,Queens,andโ€‹ Nassau Counties,New York.โค Subsidiaries include Beacon Trust Company, providing fiduciary and wealth management services, and Provident โ€Protection Plus, Inc., offering insurance services.

Contact:

Investor Relations
1-732-590-9300
http://www.Provident.Bank

0 comments
0 FacebookTwitterPinterestEmail
Business

Title: Citizens, Inc. Announces Business Update Conference Call & Webcast

by Priya Shah โ€“ Business Editor
written by Priya Shah โ€“ Business Editor

Citizens, Inc. to Host Business Update Call september 24

AUSTIN, Texas – โ€‹September 17, 2025 – Citizens, Inc. (NYSE: CIA), a diversified financial services company focused on life, โ€‹living โ€benefits, and final expense insurance, announced todayโค thatโข its management team will present a business update and host โ€a conferenceโข call and webcast on โ€ŒSeptember 24, โฃ2025,โข at โค1:45โฃ PM Eastern Time.

Tehโข call โ€will feature a presentation from Citizens’ leadership, followed by a โฃquestion-and-answerโ€‹ session forโ€Œ analysts and investors. Participants can submitโข questions in advance via โ€ https://api.newsfilecorp.com/redirect/zAwgNc8nKG.

The live โ€‹webcast, includingโ€ a slide โฃpresentation, will beโข available on the Citizens Investor โขRelations website under the โคEvents โ€Œtab: https://api.newsfilecorp.com/redirect/4YeoDt0oaE. Anโข archived โ€version of โคthe webcast willโ€ remain accessible โขon โ€Œthe website โ€‹for later viewing.

Citizens, Inc. provides life, living benefits, and โคfinal expense โขinsurance products to individuals andโฃ small businesses across the U.S., Latin America,โฃ and asia. The company serves customers in English, Spanish, Portuguese, and Mandarin. Its operations are divided into two segments: Life Insurance, โฃwhich includes international U.S. Dollar-denominated life โ€Œinsurance and U.S.โฃ final expense products, and Homeโฃ Service Insurance, primarilyโฃ operating โฃin the U.S. Gulf Coast region. citizens, Inc. is a โคcomponent of both โคthe russellโ€ 2000ยฎ and Russell 3000ยฎ indexes. further information โ€‹can be found at www.citizensinc.com โข and onโฃ LinkedIn: https://api.newsfilecorp.com/redirect/jNmzEuq3aX.

0 comments
0 FacebookTwitterPinterestEmail
Business

Dyne Therapeutics: DYNE-101 Update & Investor Call – June 17

by Priya Shah โ€“ Business Editor
written by Priya Shah โ€“ Business Editor

Dyne Therapeutics to Present DYNE-101 Update for myotonic Dystrophy Type 1

Table of Contents

WALTHAM, Mass. – June 16, 2025 – dyne Therapeutics, Inc.(Nasdaq: DYN), a company focused on developing therapies for neuromuscular diseases, announced plans to update investors on its DYNE-101 program for myotonic dystrophy type 1 (DM1). The update will be delivered tomorrow, june 17, 2025, via a live webcast scheduled for 8:00 a.m. ET. The company plans to release a press statement before the webcast begins.

Investor Conference Call and Webcast Details

The live webcast, including an accompanying slide presentation, can be accessed on the Investors & Media section of dyne’s website under Events & Presentations. A replay of the webcast will be available for 90 days following the event. To access the live webcast and replay, visit Dyne’s Investor Relations page.

Did You No? Myotonic Dystrophy Type 1 affects approximately 1 in 8,000 people worldwide, making it one of the most common forms of muscular dystrophy in adults.

About Dyne Therapeutics

Dyne Therapeutics is dedicated to creating innovative therapies for individuals affected by genetically driven neuromuscular diseases. Utilizing its FORCEโ„ข platform, dyne develops targeted therapeutics designed to improve delivery to muscle tissue and the central nervous system (CNS). The company’s pipeline includes clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD),as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD).

Dyne’s FORCEโ„ข platform is engineered to overcome limitations in drug delivery, a meaningful hurdle in treating neuromuscular diseases. This innovative approach allows for more effective targeting of affected tissues, possibly leading to better patient outcomes. Recent studies highlight the importance of targeted drug delivery in treating genetic disorders.

Dyne’s Pipeline at a glance

disease Program Status
Myotonic Dystrophy Type 1 (DM1) DYNE-101 Clinical
Duchenne Muscular Dystrophy (DMD) [Program Name] Clinical
Facioscapulohumeral Muscular Dystrophy (FSHD) [Program Name] Preclinical

pro Tip: Investors often monitor webcasts and conference calls for key insights into a company’s progress and future plans.

For more information about Dyne Therapeutics, visit https://www.dyne-tx.com/. you can also follow the company on X,LinkedIn, and Facebook.

What impact could DYNE-101 have on the lives of those living with Myotonic Dystrophy Type 1?

how crucial are investor webcasts in understanding the progress of pharmaceutical companies?

Understanding Myotonic dystrophy Type 1 (DM1)

Myotonic Dystrophy Type 1 (DM1) is a multisystemic disease, meaning it affects various parts of the body, including muscles, heart, and brain. The severity and onset of symptoms can vary widely among affected individuals. The disease is caused by an expansion of a CTG repeat in the DMPK gene, leading to RNA toxicity that disrupts normal cellular function. The National Institute of Neurological Disorders and stroke (NINDS) provides complete information on DM1.

Current treatments for DM1 primarily focus on managing symptoms, as there is no cure. These treatments can include medications for myotonia, pain management, and cardiac monitoring. Research into potential disease-modifying therapies, such as DYNE-101, offers hope for improving the long-term outcomes for individuals with DM1.

Frequently Asked Questions About Dyne Therapeutics and DYNE-101

What is the goal of Dyne Therapeutics?
Dyne Therapeutics aims to develop therapies that can transform the lives of people living with genetically driven neuromuscular diseases.
How does Dyne Therapeutics’ FORCEโ„ข platform work?
The FORCEโ„ข platform is designed to enhance the delivery of therapeutics to muscle tissue and the central nervous system, overcoming limitations in conventional drug delivery methods.
What are the potential benefits of DYNE-101?
DYNE-101 is being developed to address the underlying genetic cause of Myotonic Dystrophy Type 1 (DM1),potentially slowing or halting disease progression.
Were can I find more information about Dyne Therapeutics?
Additional information about Dyne Therapeutics can be found on their website at https://www.dyne-tx.com/.

Disclaimer: This article provides information about Dyne Therapeutics’ planned webcast and general information about their research and growth programs. It is not intended to provide medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment or care.

Stay informed about the latest developments in neuromuscular disease research! Share this article and subscribe to our newsletter for more updates.

0 comments
0 FacebookTwitterPinterestEmail
@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com